Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Certara, Inc. stock logo
CERT
Certara
$8.35
-0.7%
$7.37
$4.45
$13.88
$1.27B1.443.34 million shs2.06 million shs
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
$3.53
+0.6%
$3.21
$1.77
$5.81
$1.21B1.61.96 million shs1.00 million shs
Phreesia, Inc. stock logo
PHR
Phreesia
$12.17
+2.6%
$11.03
$7.77
$32.74
$751.02M0.85807,724 shs508,617 shs
Schrodinger, Inc. stock logo
SDGR
Schrodinger
$19.70
-3.5%
$16.89
$10.94
$23.02
$1.45B1.631.20 million shs911,492 shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Certara, Inc. stock logo
CERT
Certara
0.00%-0.95%+7.33%+43.47%-23.88%
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
0.00%+2.32%+11.36%+20.89%-21.56%
Phreesia, Inc. stock logo
PHR
Phreesia
0.00%+0.58%+14.88%+24.20%-61.97%
Schrodinger, Inc. stock logo
SDGR
Schrodinger
0.00%-0.05%+28.34%+29.61%-0.45%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Certara, Inc. stock logo
CERT
Certara
$8.35
-0.7%
$7.37
$4.45
$13.88
$1.27B1.443.34 million shs2.06 million shs
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
$3.53
+0.6%
$3.21
$1.77
$5.81
$1.21B1.61.96 million shs1.00 million shs
Phreesia, Inc. stock logo
PHR
Phreesia
$12.17
+2.6%
$11.03
$7.77
$32.74
$751.02M0.85807,724 shs508,617 shs
Schrodinger, Inc. stock logo
SDGR
Schrodinger
$19.70
-3.5%
$16.89
$10.94
$23.02
$1.45B1.631.20 million shs911,492 shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Certara, Inc. stock logo
CERT
Certara
0.00%-0.95%+7.33%+43.47%-23.88%
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
0.00%+2.32%+11.36%+20.89%-21.56%
Phreesia, Inc. stock logo
PHR
Phreesia
0.00%+0.58%+14.88%+24.20%-61.97%
Schrodinger, Inc. stock logo
SDGR
Schrodinger
0.00%-0.05%+28.34%+29.61%-0.45%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Certara, Inc. stock logo
CERT
Certara
2.42
Hold$8.28-0.86% Downside
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
2.08
Hold$4.2319.75% Upside
Phreesia, Inc. stock logo
PHR
Phreesia
2.42
Hold$16.6536.79% Upside
Schrodinger, Inc. stock logo
SDGR
Schrodinger
2.29
Hold$20.504.06% Upside

Current Analyst Ratings Breakdown

Latest PHR, SDGR, CERT, and GDRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/27/2026
Schrodinger, Inc. stock logo
SDGR
Schrodinger
UpgradeSell (E+)Sell (D-)
8/20/2026
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
Boost Price TargetUnderweight$3.00 ➝ $4.00
8/14/2026
Schrodinger, Inc. stock logo
SDGR
Schrodinger
Initiated CoverageNeutral$13.00 ➝ $19.00
8/14/2026
Schrodinger, Inc. stock logo
SDGR
Schrodinger
Initiated CoverageNeutral$13.00 ➝ $19.00
8/13/2026
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
Boost Price TargetNeutral$2.50 ➝ $3.75
8/12/2026
Schrodinger, Inc. stock logo
SDGR
Schrodinger
DowngradeSell (D-)Sell (E+)
8/11/2026
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
Boost Price TargetBuy$4.00 ➝ $5.00
8/11/2026
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
Boost Price TargetBuy$4.00 ➝ $5.00
8/7/2026
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
UpgradeSell (D)Sell (D+)
8/7/2026
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
Reiterated RatingNeutral$4.00
8/7/2026
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
Boost Price TargetOverweight$3.50 ➝ $5.00
(Data available from 8/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Certara, Inc. stock logo
CERT
Certara
$421.75M3.02$0.76 per share11.04$6.34 per share1.32
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
$796.85M1.52$0.40 per share8.82$1.89 per share1.87
Phreesia, Inc. stock logo
PHR
Phreesia
$495.59M1.52$0.75 per share16.28$5.59 per share2.18
Schrodinger, Inc. stock logo
SDGR
Schrodinger
$259.04M5.61N/AN/A$4.46 per share4.42
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Certara, Inc. stock logo
CERT
Certara
-$1.60M-$0.45N/A29.82N/A-16.75%3.86%2.65%11/5/2026 (Estimated)
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
$30.44M$0.0488.2717.651.762.07%7.22%2.53%11/3/2026 (Estimated)
Phreesia, Inc. stock logo
PHR
Phreesia
$2.31M$0.1581.1317.64N/A1.85%5.13%3.12%9/2/2026 (Estimated)
Schrodinger, Inc. stock logo
SDGR
Schrodinger
-$103.26M-$0.74N/AN/AN/A-20.98%-16.37%-8.19%11/4/2026 (Estimated)

Latest PHR, SDGR, CERT, and GDRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
9/2/2026Q2 2027
Phreesia, Inc. stock logo
PHR
Phreesia
$0.11N/AN/AN/A$129.07 millionN/A
8/5/2026Q2 2026
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
$0.0797$0.08+$0.0003$0.02$193.23 million$200.41 million
8/5/2026Q2 2026
Schrodinger, Inc. stock logo
SDGR
Schrodinger
-$0.4145$0.08+$0.4945$0.08$47.19 million$58.89 million
8/4/2026Q2 2026
Certara, Inc. stock logo
CERT
Certara
$0.0893$0.08-$0.0093-$0.36$98.09 million$93.27 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Certara, Inc. stock logo
CERT
Certara
N/AN/AN/AN/AN/A
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
N/AN/AN/AN/AN/A
Phreesia, Inc. stock logo
PHR
Phreesia
N/AN/AN/AN/AN/A
Schrodinger, Inc. stock logo
SDGR
Schrodinger
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Certara, Inc. stock logo
CERT
Certara
0.30
2.55
2.55
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
0.74
1.38
1.38
Phreesia, Inc. stock logo
PHR
Phreesia
0.41
1.76
1.76
Schrodinger, Inc. stock logo
SDGR
Schrodinger
N/A
2.71
2.71

Institutional Ownership

CompanyInstitutional Ownership
Certara, Inc. stock logo
CERT
Certara
73.96%
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
63.77%
Phreesia, Inc. stock logo
PHR
Phreesia
92.10%
Schrodinger, Inc. stock logo
SDGR
Schrodinger
79.05%

Insider Ownership

CompanyInsider Ownership
Certara, Inc. stock logo
CERT
Certara
1.08%
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
5.87%
Phreesia, Inc. stock logo
PHR
Phreesia
5.20%
Schrodinger, Inc. stock logo
SDGR
Schrodinger
10.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Certara, Inc. stock logo
CERT
Certara
1,576152.54 million150.89 millionOptionable
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
950342.57 million322.47 millionOptionable
Phreesia, Inc. stock logo
PHR
Phreesia
1,78961.81 million58.60 millionOptionable
Schrodinger, Inc. stock logo
SDGR
Schrodinger
79073.83 million66.37 millionOptionable

Recent News About These Companies

BlackRock Inc. Buys New Shares in Schrodinger, Inc. $SDGR
Algert Global LLC Trims Stake in Schrodinger, Inc. $SDGR
Morgan Stanley Keeps Their Hold Rating on Schrodinger (SDGR)
BMO Capital Reaffirms Their Buy Rating on Schrodinger (SDGR)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Certara stock logo

Certara NASDAQ:CERT

$8.35 -0.06 (-0.71%)
As of 08/28/2026 04:00 PM Eastern

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.

GoodRx stock logo

GoodRx NASDAQ:GDRX

$3.53 +0.02 (+0.57%)
As of 08/28/2026 04:00 PM Eastern

GoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices. It also offers other healthcare products and services, including subscriptions, and pharma manufacturer solutions, as well as telehealth services through the GoodRx Care platform. It serves pharmacy benefit managers who manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was founded in 2011 and is headquartered in Santa Monica, California.

Phreesia stock logo

Phreesia NYSE:PHR

$12.17 +0.31 (+2.61%)
As of 08/28/2026 03:58 PM Eastern

Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients. The company deploys its platform in a range of modalities, such as Phreesia Mobile, a patients' mobile device; Phreesia Dashboard, a web-based dashboard for healthcare services clients; PhreesiaPads, a self-service intake tablets; and Arrivals Kiosks, an on-site kiosks. It serves patients; single-specialty practices, multi-specialty groups, and health systems; and pharmaceutical, medical device, and biotechnology companies. The company was incorporated in 2005 and is based in Wilmington, Delaware.

Schrodinger stock logo

Schrodinger NASDAQ:SDGR

$19.70 -0.71 (-3.48%)
As of 08/28/2026 04:00 PM Eastern

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.